Research Highlights: Dapagliflozin Correlated with Low Risk of Unfavorable Kidney and Cardiovascular Outcomes


Related Posts


Original Article: https://doi.org/10.1056/nejmoa2024816

  • Patients with chronic kidney disease have a high risk of unfavorable kidney and cardiovascular consequences.
  • Researchers do not know the effect of dapagliflozin in patients (with or without type 2 diabetes) with chronic kidney disease.
  • Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2.
  • The study involves 4304 participants with glomerular filtration rate and urinary albumin-to-creatinine ratio assessed.
  • The participants were randomly assigned to receive dapagliflozin or placebo.
  • The primary outcome was a combination of a sustained reduction in the estimated glomerular filtration rate of at least 50 percent, end-stage kidney disease, or death from renal or cardiovascular disease.
  • The trial was stopped because of efficacy.
  • Primary outcome event occurred in 197 of 2152 participants in the dapagliflozin group.
  • Primary outcome event occurred in 312 of 2152 participants in the placebo group.
  • Death occurred in 101 participants in the dapagliflozin group.
  • Death occurred in 146 participants in the placebo group.
  • The effects of dapagliflozin were similar in participants with type 2 diabetes and in those without type 2 diabetes.
  • The study concluded that dapagliflozin is correlated with lower risk of a composite of a sustained decline in the estimated glomerular filtration rate of at least 50 percent, end-stage kidney disease, or death from renal or cardiovascular causes.

Source:

https://doi.org/10.1056/nejmoa2024816

https://pubmed.ncbi.nlm.nih.gov/19996149/


Advertisements

Advertisements

Leave a Reply

Your email address will not be published.